Home » Newsletters » BioWorld

BioWorld

Jan. 28, 1992

View Archived Issues

GYNEX TO USE VA DATA IN FDA REVIEW

CYTRX TO REDEEM CLASS B WARRANTS

UNIGENE PLANS CALCITONIN SALES

DNAP TO ACQUIRE JOINT VENTURE

YAMANOUCHI TO SELL ABS TEST KITS

STEM CELL CONCENTRATOR SUCCESSFUL IN TESTS

INSITE TO EYE SYNERGEN'S ANTRIL

CARRINGTON REPORTS PROFITABLE YEAR

BUSH TO DISCUSS BIOTECH INITIATIVE

AMYLIN RECEIVES FIRST PATENT NOTICE

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...